c-Fms-IN-10 is the derivative of thieno [3,2-d] pyrimidine, an kinase inhibitor of FMS (Colony stimulating factor-1 receptor, CSF-1R) with IC₅₀ of 2 nM. c-Fms-IN-10 has anti-tumor activity^[1].

429.50

C₂₂H₁₉N₇OS

1527517-50-5

Room temperature in continental US; may vary elsewhere.

DMSO : 10 mg/mL (23.28 mM; ultrasonic and warming and heat to 60°C)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

  Solubility: 1 mg/mL (2.33 mM); Suspended solution; Need ultrasonic

  此方案可获得 1 mg/mL (2.33 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

  以 1 mL 工作液为例，取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

  将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

• 2.

  请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

  Solubility: 1 mg/mL (2.33 mM); Suspended solution; Need ultrasonic

  此方案可获得 1 mg/mL (2.33 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

  以 1 mL 工作液为例，取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

  将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明

• [1]. Kim YY， et al. Synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel FMS inhibitors. Bioorg Med Chem Lett. 2019 Jan 15;29(2):271-275.

c-Fms-IN-9 is a c-FMS inhibitor extracted from patent WO2014145023A1, Compound Example 7. c-Fms-IN-9 inhibits unphosphorylated c-FMS kinase (uFMS) and uKIT with IC₅₀s of <0.01 μM and 0.1-1 μM, respectively^[1].

c-FMS^[1]

c-Fms-IN-9 inhibits M-NFS-60, THP-1 and osteoclast cells proliferation with IC₅₀s of 0.01-0.1 μM^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

405.45

C₂₁H₂₃N₇O₂

1628574-50-4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Gary E. L. BRANDT, et al. 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities. WO2014145023A1.

c-Fms-IN-9 is a c-FMS inhibitor extracted from patent WO2014145023A1, Compound Example 7. c-Fms-IN-9 inhibits unphosphorylated c-FMS kinase (uFMS) and uKIT with IC₅₀s of <0.01 μM and 0.1-1 μM, respectively^[1].

c-FMS^[1]

c-Fms-IN-9 inhibits M-NFS-60, THP-1 and osteoclast cells proliferation with IC₅₀s of 0.01-0.1 μM^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

405.45

C₂₁H₂₃N₇O₂

1628574-50-4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Gary E. L. BRANDT, et al. 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities. WO2014145023A1.

c-Fms-IN-9 is a c-FMS inhibitor extracted from patent WO2014145023A1, Compound Example 7. c-Fms-IN-9 inhibits unphosphorylated c-FMS kinase (uFMS) and uKIT with IC₅₀s of <0.01 μM and 0.1-1 μM, respectively^[1].

c-FMS^[1]

c-Fms-IN-9 inhibits M-NFS-60, THP-1 and osteoclast cells proliferation with IC₅₀s of 0.01-0.1 μM^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

405.45

C₂₁H₂₃N₇O₂

1628574-50-4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Gary E. L. BRANDT, et al. 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities. WO2014145023A1.